296 related articles for article (PubMed ID: 36949463)
1. The IL-33:ST2 axis is unlikely to play a central fibrogenic role in idiopathic pulmonary fibrosis.
Stephenson KE; Porte J; Kelly A; Wallace WA; Huntington CE; Overed-Sayer CL; Cohen ES; Jenkins RG; John AE
Respir Res; 2023 Mar; 24(1):89. PubMed ID: 36949463
[TBL] [Abstract][Full Text] [Related]
2. An ST2-dependent role of bone marrow-derived group 2 innate lymphoid cells in pulmonary fibrosis.
Zhao Y; De Los Santos FG; Wu Z; Liu T; Phan SH
J Pathol; 2018 Aug; 245(4):399-409. PubMed ID: 29722022
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of RUNX1 blocks the differentiation of lung fibroblasts to myofibroblasts.
Dubey S; Dubey PK; Umeshappa CS; Ghebre YT; Krishnamurthy P
J Cell Physiol; 2022 Apr; 237(4):2169-2182. PubMed ID: 35048404
[TBL] [Abstract][Full Text] [Related]
4. The anti-fibrotic effect of inhibition of TGFβ-ALK5 signalling in experimental pulmonary fibrosis in mice is attenuated in the presence of concurrent γ-herpesvirus infection.
Smoktunowicz N; Alexander RE; Franklin L; Williams AE; Holman B; Mercer PF; Jarai G; Scotton CJ; Chambers RC
Dis Model Mech; 2015 Sep; 8(9):1129-39. PubMed ID: 26138704
[TBL] [Abstract][Full Text] [Related]
5. Vorapaxar proven to be a promising candidate for pulmonary fibrosis by intervening in the PAR1/JAK2/STAT1/3 signaling pathway-an experimental in vitro and vivo study.
Xiao T; Ren S; Bao J; Gao D; Sun R; Gu X; Gao J; Chen S; Jin J; Wei L; Wu C; Yang C; Yang G; Zhou H
Eur J Pharmacol; 2023 Mar; 943():175438. PubMed ID: 36682482
[TBL] [Abstract][Full Text] [Related]
6. IL-33/ST2 axis contributes to the dermal fibrosis of systemic sclerosis via promoting fibroblasts activation.
Wu X; Ming B; Wu T; Gao R; Hu P; Tang J; Zhong J; Zheng F; Dong L
J Dermatol Sci; 2022 Aug; 107(2):95-104. PubMed ID: 35940987
[TBL] [Abstract][Full Text] [Related]
7. miR-199a-5p Is upregulated during fibrogenic response to tissue injury and mediates TGFbeta-induced lung fibroblast activation by targeting caveolin-1.
Lino Cardenas CL; Henaoui IS; Courcot E; Roderburg C; Cauffiez C; Aubert S; Copin MC; Wallaert B; Glowacki F; Dewaeles E; Milosevic J; Maurizio J; Tedrow J; Marcet B; Lo-Guidice JM; Kaminski N; Barbry P; Luedde T; Perrais M; Mari B; Pottier N
PLoS Genet; 2013; 9(2):e1003291. PubMed ID: 23459460
[TBL] [Abstract][Full Text] [Related]
8. Tubastatin ameliorates pulmonary fibrosis by targeting the TGFβ-PI3K-Akt pathway.
Saito S; Zhuang Y; Shan B; Danchuk S; Luo F; Korfei M; Guenther A; Lasky JA
PLoS One; 2017; 12(10):e0186615. PubMed ID: 29045477
[TBL] [Abstract][Full Text] [Related]
9. Secretoglobin 3A2 Exhibits Anti-Fibrotic Activity in Bleomycin-Induced Pulmonary Fibrosis Model Mice.
Cai Y; Kimura S
PLoS One; 2015; 10(11):e0142497. PubMed ID: 26559674
[TBL] [Abstract][Full Text] [Related]
10. Mimosa pudica L. extract ameliorates pulmonary fibrosis via modulation of MAPK signaling pathways and FOXO3 stabilization.
Nguyen QC; Nguyen HA; Pham TA; Tran VT; Nguyen TD; Pham DV
J Ethnopharmacol; 2024 Aug; 330():118226. PubMed ID: 38670401
[TBL] [Abstract][Full Text] [Related]
11. The heterodimer S100A8/A9 is a potent therapeutic target for idiopathic pulmonary fibrosis.
Araki K; Kinoshita R; Tomonobu N; Gohara Y; Tomida S; Takahashi Y; Senoo S; Taniguchi A; Itano J; Yamamoto KI; Murata H; Suzawa K; Shien K; Yamamoto H; Okazaki M; Sugimoto S; Ichimura K; Nishibori M; Miyahara N; Toyooka S; Sakaguchi M
J Mol Med (Berl); 2021 Jan; 99(1):131-145. PubMed ID: 33169236
[TBL] [Abstract][Full Text] [Related]
12. CCN5 overexpression inhibits profibrotic phenotypes via the PI3K/Akt signaling pathway in lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis and in an in vivo model of lung fibrosis.
Zhang L; Li Y; Liang C; Yang W
Int J Mol Med; 2014 Feb; 33(2):478-86. PubMed ID: 24276150
[TBL] [Abstract][Full Text] [Related]
13. Blockade of platelet-derived growth factor receptor-β, not receptor-α ameliorates bleomycin-induced pulmonary fibrosis in mice.
Kishi M; Aono Y; Sato S; Koyama K; Azuma M; Abe S; Kawano H; Kishi J; Toyoda Y; Okazaki H; Ogawa H; Uehara H; Nishioka Y
PLoS One; 2018; 13(12):e0209786. PubMed ID: 30596712
[TBL] [Abstract][Full Text] [Related]
14. Precision-cut lung slices from bleomycin treated animals as a model for testing potential therapies for idiopathic pulmonary fibrosis.
Cedilak M; Banjanac M; Belamarić D; Paravić Radičević A; Faraho I; Ilić K; Čužić S; Glojnarić I; Eraković Haber V; Bosnar M
Pulm Pharmacol Ther; 2019 Apr; 55():75-83. PubMed ID: 30776489
[TBL] [Abstract][Full Text] [Related]
15. An ex vivo model to induce early fibrosis-like changes in human precision-cut lung slices.
Alsafadi HN; Staab-Weijnitz CA; Lehmann M; Lindner M; Peschel B; Königshoff M; Wagner DE
Am J Physiol Lung Cell Mol Physiol; 2017 Jun; 312(6):L896-L902. PubMed ID: 28314802
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the stem cell factor 248 isoform attenuates the development of pulmonary remodeling disease.
Rasky A; Habiel DM; Morris S; Schaller M; Moore BB; Phan S; Kunkel SL; Phillips M; Hogaboam C; Lukacs NW
Am J Physiol Lung Cell Mol Physiol; 2020 Jan; 318(1):L200-L211. PubMed ID: 31747308
[TBL] [Abstract][Full Text] [Related]
17. TGF-β pathway activation by idiopathic pulmonary fibrosis (IPF) fibroblast derived soluble factors is mediated by IL-6 trans-signaling.
Epstein Shochet G; Brook E; Bardenstein-Wald B; Shitrit D
Respir Res; 2020 Feb; 21(1):56. PubMed ID: 32070329
[TBL] [Abstract][Full Text] [Related]
18. The Protective Effects of IL-31RA Deficiency During Bleomycin-Induced Pulmonary Fibrosis.
Yombo DJK; Odayar V; Gupta N; Jegga AG; Madala SK
Front Immunol; 2021; 12():645717. PubMed ID: 33815402
[TBL] [Abstract][Full Text] [Related]
19. Compromised peroxisomes in idiopathic pulmonary fibrosis, a vicious cycle inducing a higher fibrotic response via TGF-β signaling.
Oruqaj G; Karnati S; Vijayan V; Kotarkonda LK; Boateng E; Zhang W; Ruppert C; Günther A; Shi W; Baumgart-Vogt E
Proc Natl Acad Sci U S A; 2015 Apr; 112(16):E2048-57. PubMed ID: 25848047
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow mesenchymal stem cell-derived exosomes alleviate skin fibrosis in systemic sclerosis by inhibiting the IL-33/ST2 axis via the delivery of microRNA-214.
Xie L; Long X; Mo M; Jiang J; Zhang Q; Long M; Li M
Mol Immunol; 2023 May; 157():146-157. PubMed ID: 37028129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
